EXOSC3

Across TCGA pan-cancer cohorts, EXOSC3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EXOSC3 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EXOSC3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EXOSC3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where EXOSC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.990	0.817	.002	29	view →
PDAC	DFS	Median	III,IV	0.486	0.844	.007	11	view →
CCRCC	DFS	Median	All	0.704	1.000	.008	7	view →
GBM	DFS	Median	All	0.286	0.454	.038	3	view →
HNSC	DFS	Median	All	0.980	0.907	.043	3	view →
LSCC	DFS	Median	II,III,IV	0.812	0.598	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EXOSC3–LUAD (DFS)

Open the LUAD breakdown →